Categories
Change Password!
Reset Password!
Empagliflozin also not found to increase the
risk of fractures among T2DM patients. The study outcomes with Empagliflozin
were similar to Glimeperide and placebo.
As per a
recently published study in Diabetes Care, the Empagliflozin therapy does not
increase the risk of fractures in type 2 diabetes patients.
In 2014, Empagliflozin (drug of the gliflozin class) was approved for the
treatment of type 2 diabetes in adults. It is a
reversible, highly active, selective and competitive inhibitor of the
sodium-dependent glucose transporter of type 2.
Sven Kohler, M.D., from Boehringer Ingelheim International in Germany, and
researchers investigated the effect of Empagliflozin on bone fracture adverse
events (AEs) and bone mineral density (BMD) in type 2 diabetes patients. They
took data from a placebo-controlled trial (1:1:1; Empagliflozin 10 mg,
Empagliflozin 25 mg, or placebo in phase I to III clinical trials) comprising more
than 4,000 participants.
Bone
fractures were diagnosed in 2.8% participants of 10 mg group, 2.5% in the 25 mg
group of Empagliflozin and 2.9% in the placebo group. Fractures were noted in
4.1% and 4.2% of participants in a comparative study of Empagliflozin and
Glimepiride. Thus no significant difference was found in fracture risk in any
of the three groups showing that Empagliflozin is not associated with
increasing the risk of fracture in type 2 diabetes patients.
Remedium
Study: therapy with empaglyflosin does not increase the risk of fractures
Comments (0)